Evidence & Research Status
Researchers studying NAD+ decline are increasingly focused on the enzymes responsible for it — not just the coenzyme’s role once it’s gone, but the biochemical mechanisms that drain it in the first…
Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.
Researchers studying NAD+ decline are increasingly focused on the enzymes responsible for it — not just the coenzyme’s role once it’s gone, but the biochemical mechanisms that drain it in the first place. Three enzyme families keep showing up in the 2026 literature: CD38, NAMPT, and the PARP family, and each tells a different part of the story about why cellular NAD+ levels fall with age.
Why NAD+ Decline Happens in the First Place
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every cell needs for energy metabolism, DNA repair, and mitochondrial function. Researchers have long observed that tissue NAD+ levels fall with age, but the more interesting question — and the one driving current research, as summarized in a recent NAD+/NNMT research review — is why. It’s not simply that cells stop making NAD+. Instead, the prevailing model is that NAD+-consuming enzymes become more active over time, depleting the pool faster than biosynthesis pathways like the salvage pathway (via NAMPT and NMN) can replace it.
CD38: The Enzyme Getting the Most Research Attention
CD38 is a cell-surface enzyme that both consumes NAD+ directly and produces signaling molecules like cyclic ADP-ribose. Findings across aging research consistently show CD38 activity rising with age and with chronic low-grade inflammation — a pattern sometimes called “inflammaging.” Because CD38 is expressed on immune cells and increases during inflammatory states, researchers have proposed it as a mechanistic link between age-related inflammation and falling NAD+ levels. Several academic groups are now screening small-molecule CD38 inhibitors specifically to see whether blocking the enzyme preserves tissue NAD+ pools in animal models.
NAMPT: The Rate-Limiting Step in NAD+ Recycling
Where CD38 breaks NAD+ down, NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme in putting it back together via the salvage pathway. Research groups have observed that NAMPT expression and activity also decline with age in multiple tissue types, meaning older cells are being squeezed from both directions — more breakdown from CD38, less recycling from NAMPT. This is part of why NAD+ precursor supplementation (NR, NMN) has become a research focus: precursors feed into the same salvage pathway that NAMPT operates, potentially offsetting reduced recycling capacity.
PARPs: DNA Repair’s Trade-Off With NAD+ Supply
The PARP (poly-ADP-ribose polymerase) family consumes NAD+ as a substrate during DNA repair. This is a legitimate and necessary use of NAD+, but researchers studying accumulated DNA damage over a lifespan have noted that increased PARP activation in aging or stressed tissue can meaningfully compete with other NAD+-dependent processes, including the sirtuins involved in mitochondrial regulation. Some 2026 papers frame this as a resource-allocation problem: as DNA damage accumulates, more of the shrinking NAD+ pool gets diverted to repair, leaving less for metabolic regulation.
Enzyme Targets at a Glance
| Enzyme | Role in NAD+ Decline | Current Research Focus |
|---|---|---|
| CD38 | Directly consumes NAD+; activity rises with age and inflammation | Small-molecule inhibitor screening |
| NAMPT | Rate-limiting enzyme in NAD+ salvage/recycling; expression falls with age | Precursor (NR/NMN) delivery to support salvage pathway flux |
| PARP family | Consumes NAD+ during DNA repair; competes with sirtuins for supply | Understanding resource competition in aged/stressed tissue |
What This Means for Longevity and Mitochondrial Research
The enzyme-targeting angle matters because it reframes NAD+ research beyond simple supplementation. Rather than only asking “how do we add more NAD+,” researchers are increasingly asking “how do we slow the enzymes that remove it.” That distinction matters for anyone tracking the mitochondrial and longevity peptide space — compounds like MOTS-c, which researchers are studying for its role in mitochondrial stress signaling, sit adjacent to this same biology, since mitochondrial function and NAD+ availability are tightly linked.
Open Questions for Researchers
Several questions remain open in this research area: whether CD38 inhibition produces measurable NAD+ preservation in human tissue rather than just animal models; whether NAMPT-boosting strategies and precursor supplementation are additive or redundant; how PARP activation from accumulated DNA damage should be weighed against its clear protective role in genome stability; and whether enzyme-level interventions will ultimately outperform simple precursor supplementation, or whether the two approaches are complementary rather than competing strategies.
The Bottom Line
NAD+ decline isn’t a single mechanism — it’s the net effect of rising consumption (CD38, PARPs) and falling recycling capacity (NAMPT), layered on top of whatever precursor supply is available. As research groups continue to publish on enzyme-targeted approaches alongside precursor-based strategies, the field is moving toward a more mechanistic understanding of why NAD+ falls with age — and more precise ways to study intervening in that process.
All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.